

PRODUCT INFORMATION

Common Name	MEDI0562
Conjugate	Unconjugated
Synonyms	TNFRSF4, TXGP1L, CD134, ACT35 antigen, OX40L receptor
Applications	ELISA, Flow Cyt
Endotoxin	Less than 1.0 EU/µg by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Recommended Dilutions	ELISA 1:5000-10000, Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Chimeric Humanized
IgG type	Human IgG1 - kappa
Reactivity	Human
Target	OX40
Uniprot ID	P43489
Description	Anti-OX40(tavolimab biosimilar) mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature.
Sterility	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 µm) prior to use.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only






Figure 1. Flow cytometry analysis with 0.5 µg/mL Anti-OX40(tavolimab biosimilar) mAb (BME100047) on HEK293 cells transfected with Human OX40 protein (Blue histogram) or HEK293 transfected with irrelevant protein (Red histogram).

Anti-OX40(tavolimab biosimilar)mAb ELISA

0.2 µg of Human OX40, hFc-His tagged protein per well




Figure 2. ELISA plate pre-coated by 2 µg/mL (100 µL/well) Human OX40 Protein, hFc-His Tag (PME100022) can bind Anti-OX40(tavolimab biosimilar)mAb (BME100047) in a linear range of 0.76-20.58 ng/mL.

